Bristol-Myers Squibb Announces Dividend Increase
December 08 2016 - 4:15PM
Business Wire
The Board of Directors of Bristol-Myers Squibb Company
(NYSE:BMY) today declared an increase of 2.6% percent in the
company’s quarterly dividend, beginning in the first quarter of
2017.
The dividend increase will result in a quarterly dividend of
thirty nine cents ($0.39) per share on the $.10 par value Common
Stock of the corporation. The next quarterly dividend will be
payable on February 1, 2017, to stockholders of record at the close
of business on January 6, 2017.
The directors also declared a quarterly dividend of fifty cents
($0.50) per share on the $2.00 Convertible Preferred Stock of the
corporation, payable March 1, 2017 to stockholders of record at the
close of business on February 7, 2017.
The directors indicated an expected dividend for the full year
of 2017 of $1.56 per share on the $.10 par value Common Stock of
the corporation, subject to the normal quarterly review by the
Board.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us
at BMS.com or follow us on LinkedIn, Twitter,
YouTube and Facebook.
Forward-looking
Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. Such forward-looking statements are based on current
expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them,
and could cause actual outcomes and results to differ materially
from current expectations. No forward-looking statement can be
guaranteed. Among other risks, there can be no guarantee that the
Board will approve a quarterly dividend in future quarters or that
the dividend for the full year of 2017 will be the amount indicated
in this press release. Forward-looking statements in this press
release should be evaluated together with the many uncertainties
that affect Bristol-Myers Squibb's business, particularly those
identified in the cautionary factors discussion in Bristol-Myers
Squibb's Annual Report on Form 10-K for the year ended December 31,
2015, in our Quarterly Reports on Form 10-Q and our Current Reports
on Form 8-K. Bristol-Myers Squibb undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161208005994/en/
Bristol-Myers Squibb CompanyMedia:Ken Dominski,
609-252-5251ken.dominski@bms.comorLisa McCormick Lavery,
609-252-7602lisa.mccormicklavery@bms.comorInvestors:Tim
Power, 609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024